+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 153 Actively Recruiting clinical trials

L

Actively Recruiting

This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.

Age: 18Years - 65YearsAll GendersPhase 3
23 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.

Age: 18Years +All GendersPhase 2Phase 3
56 locations
E

Actively Recruiting

Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.

Age: 18Years +All GendersPhase 1Phase 2
54 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
O

Actively Recruiting

Researchers are evaluating zanidatamab for the treatment of adults with previously treated solid tumors that show high levels of HER2 protein IHC 3 overexpression. This phase 2, open-label study focuses on participants whose cancers have progressed despite prior systemic treatments and who have no confirmed beneficial treatment options left. Participants receive zanidatamab administered by intravenous infusion. The study includes participants with various HER2-expressing solid tumors, excluding biliary tract cancers. Some cohorts allow prior HER2-targeted therapy, while others do not. Treatment continues with monitoring for up to 2.5 years to evaluate response and safety. During the study, participants undergo regular assessments including tumor evaluations by independent central review and investigator assessment using RECIST 1.1 criteria. Researchers monitor objective response rates, duration and time to response, disease control, progression-free and overall survival, and treatment-emergent adverse events. Blood samples measure zanidatamab concentration and antibody development. Participants are followed for safety and treatment effects for up to 3.5 years.

Age: 18Years +All GendersPhase 2
42 locations
P

Actively Recruiting

Researchers are evaluating zelquistinel, a drug aimed at reducing symptoms of major depressive disorder in adults aged 18 to 64 years. This Phase 2 clinical trial compares the effects and safety of zelquistinel to a placebo in participants diagnosed with major depressive disorder. The study will focus on changes in depression severity and monitor any medical issues that arise during treatment. Participants will take one tablet of either zelquistinel or placebo once a week for six weeks. The trial includes a screening period of up to 28 days, followed by a 42-day treatment phase, and then a four-week follow-up period. During treatment, participants will visit the clinic weekly to receive their dose and have their depression symptoms assessed using the Hamilton Depression Rating Scale-17. Throughout the study, participants will have their depression severity regularly evaluated, along with monitoring for adverse events or side effects. The study lasts up to 98 days, including screening, treatment, and follow-up. Researchers will measure changes in depression scores from the beginning to the end of treatment and monitor overall safety during this time.

Age: 18Years - 64YearsAll GendersPhase 2
32 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations

1-10 of 153

1